Integrated Optical Coherence Tomography and Microscopy for Molecular-Targeted Ima

用于分子靶向成像的集成光学相干断层扫描和显微镜

基本信息

批准号：
8475595
负责人：
Chao Zhou
金额：
$ 22.97万
依托单位：
LEHIGH UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-06-01 至 2015-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8475595
关键词：
Animal Model Antibodies Binding Biodistribution Biological Cancer Detection Cardiovascular Diseases Cell Culture Techniques Cells Confocal Microscopy Contrast Media Data Set Detection Development Epidermal Growth Factor Receptor Frequencies Glutamate Carboxypeptidase II Goals Histology Histopathology Human Image Imagery Imaging Techniques Imaging technology Instruction Lasers Ligands Methods Microscopy Molecular Molecular Target Morphology Nanotechnology Neurodegenerative Disorders Noise Optical Coherence Tomography Optics Pathology Performance Phase Proteins Protocols documentation Research Resolution Screening for cancer Sensitivity and Specificity Signal Transduction Source Specimen Specimen Handling Speed Staging Structure System Techniques Technology Therapeutic Time Tissues Toxic effect absorption base cancer cell cytotoxicity design imaging modality improved in vivo nanoparticle neoplastic novel phase change programs protein expression small molecule tool tumor tumor progression

项目摘要

Optical coherence tomography (OCT) is a powerful tool for assessing three-dimensional (3D) tissue architectural morphology in vivo and in real-time, with a resolution approaching that of standard histopathology. Optical coherence microscopy (OCM) combines OCT with confocal microscopy in order to achieve high transverse resolution and 3D visualization of cellular features. However, current OCT and OCM imaging technologies have not been able to leverage the advances in molecular-targeted contrast agents because there is no. known method to generate molecular contrast using OCT and OCM. Our hypothesis is that 3D, multi-scale OCT and OCM, in combination with molecular-targeted contrast agents, will improve the sensitivity and specificity of early cancer detection. The goal of this program is to develop the technology that will enable molecular contrast for 3D-0CT and OCM imaging, building upon preliminary studies. This program will vertically integrate technical development in OCT and OCM, and leverage recent advances in molecular-targeted contrast agents and nanotechnology. The successful completion of this program will: 1) transform the OCT field by enabling molecularly sensitive contrast and 3D structural imaging; 2) open the way for the highly sensitive and specific detection of cancer markers that can be readily combined with photothermal therapeutic techniques; and 3) serve as a launching point for additional OCT and OCM studies of other pathologies associated with abnormal protein expression levels, such as neurodegenerative and cardiovascular diseases. These advances will enable both the structure and pathological states of tissue to be imaged in 3D, in vivo, in real time, and with micron-level spatial resolutions at multiple scales.

光学相干断层扫描 (OCT) 是一种强大的工具，用于实时评估体内三维 (3D) 组织结构形态，其分辨率接近标准组织病理学的分辨率。光学相干显微镜 (OCM) 将 OCT 与共焦显微镜相结合，以实现细胞特征的高横向分辨率和 3D 可视化。然而，当前的 OCT 和 OCM 成像技术还无法利用分子靶向造影剂的进步，因为没有。使用 OCT 和 OCM 生成分子对比的已知方法。我们的假设是，3D、多尺度 OCT 和 OCM 与分子靶向造影剂相结合，将提高早期癌症检测的灵敏度和特异性。该项目的目标是在初步研究的基础上开发能够实现 3D-0CT 和 OCM 成像分子对比的技术。该计划将垂直整合 OCT 和 OCM 的技术开发，并利用分子靶向造影剂和纳米技术的最新进展。该项目的成功完成将：1）通过实现分子敏感对比和 3D 结构成像来改变 OCT 领域； 2）为癌症标志物的高灵敏度和特异性检测开辟了道路，可以轻松地与光热治疗技术相结合； 3) 作为与蛋白质表达水平异常相关的其他病理学（例如神经退行性疾病和心血管疾病）的其他 OCT 和 OCM 研究的启动点。这些进步将使组织的结构和病理状态能够在多个尺度上以微米级空间分辨率在体内实时进行 3D 成像。